Trial Profile
Phase I Study of Intraperitoneal Radioimmunotherapy With 131I-8H9 for Patients With Desmoplastic Small Round Cell Tumors and Other Solid Tumors Involving the Peritoneum
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 03 Nov 2023
Price :
$35
*
At a glance
- Drugs Omburtamab-I-131 (Primary)
- Indications Adrenocortical carcinoma; Ewing's sarcoma; Peritoneal cancer; Rhabdomyosarcoma; Soft tissue sarcoma; Solid tumours; Wilms' tumour
- Focus Adverse reactions
- Sponsors Y-mAbs Therapeutics
- 26 Oct 2023 Status changed from active, no longer recruiting to discontinued.
- 08 Mar 2023 Planned End Date changed from 1 Sep 2022 to 1 Sep 2023.
- 07 Feb 2022 Planned End Date changed from 1 Sep 2021 to 1 Sep 2022.